These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19364050)

  • 21. Mechanisms of resistance to HER2 target therapy.
    Tortora G
    J Natl Cancer Inst Monogr; 2011; 2011(43):95-8. PubMed ID: 22043051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER2011: the changing face of HER2-positive breast cancer.
    Sledge GW
    Clin Breast Cancer; 2011 Mar; 11(1):9. PubMed ID: 21421515
    [No Abstract]   [Full Text] [Related]  

  • 23. Her2-positive breast cancer: herceptin and beyond.
    Dean-Colomb W; Esteva FJ
    Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.
    Ferretti G; Fabi A; Felici A; Papaldo P
    J Clin Oncol; 2010 Jul; 28(20):e337; author reply e338-9. PubMed ID: 20479395
    [No Abstract]   [Full Text] [Related]  

  • 25. Outcomes following adjuvant therapy for HER2-positive early breast cancer in the elderly.
    Otter S; Ring A
    Expert Rev Anticancer Ther; 2010 Aug; 10(8):1265-72. PubMed ID: 20735312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical practice-changing trials: the HERA study paradigm.
    Zardavas D; Ades F; de Azambuja E
    Expert Rev Anticancer Ther; 2013 Nov; 13(11):1249-56. PubMed ID: 24138446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Strategies of breast cancer treatment based on determination of biological subtype].
    Semiglazov VF
    Vopr Onkol; 2011; 57(5):542-52. PubMed ID: 22238922
    [No Abstract]   [Full Text] [Related]  

  • 29. [Prevention strategies for brain metastases from HER2-positive breast cancer].
    Le Tourneau C
    Bull Cancer; 2011 Apr; 98(4):445-9. PubMed ID: 21540148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The distinctive nature of HER2-positive breast cancers.
    Burstein HJ
    N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
    [No Abstract]   [Full Text] [Related]  

  • 31. Neratinib (HKI-272) in the treatment of breast cancer.
    López-Tarruella S; Jerez Y; Márquez-Rodas I; Martín M
    Future Oncol; 2012 Jun; 8(6):671-81. PubMed ID: 22764764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Very small breast cancer, HER2 positive, and trastuzumab in adjuvant treatment].
    Vyzula R
    Klin Onkol; 2010; 23(1):21-4. PubMed ID: 20192070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer.
    Araki K; Saji S; Gallas M; Pegram M; Sasaki Y
    Breast Cancer; 2012 Apr; 19(2):95-103. PubMed ID: 21863310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL; Kümler I; Palshof JA; Andersson M
    Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lapatinib in breast cancer: clinical experiences and future perspectives.
    Giampaglia M; Chiuri VE; Tinelli A; De Laurentiis M; Silvestris N; Lorusso V
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S72-9. PubMed ID: 21129615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.
    Tomasello G; Bedard PL; de Azambuja E; Lossignol D; Devriendt D; Piccart-Gebhart MJ
    Crit Rev Oncol Hematol; 2010 Aug; 75(2):110-21. PubMed ID: 20004109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2-positive advanced breast cancer.
    Robert NJ; Favret AM
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):293-302. PubMed ID: 17512450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study.
    Olszewski AJ; Migdady Y; Boolbol SK; Klein P; Boachie-Adjei K; Sakr BJ; Sikov W; Shao T
    Breast Cancer Res Treat; 2013 Feb; 138(1):215-23. PubMed ID: 23354365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
    Tuma RS
    J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
    [No Abstract]   [Full Text] [Related]  

  • 40. Adjuvant anthracyclines: time for a change of heart?
    O'Regan R
    Oncology (Williston Park); 2011 Feb; 25(2):140, 142. PubMed ID: 21456385
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.